Abstract：Objective: To investigate the clinical effect of neoadjuvant chemotherapy combined with breast conserving surgery on patients with early-stage breast cancer.Methods: A total of 90 patients with early-stage breast cancer in our hospital from January 2018 to December 2021 were selected and randomly divided into the control group of 45 cases and the observation group of 45 cases according to the random number table method. The control group was treated with breast conserving surgery only, and the observation group was treated with neoadjuvant chemotherapy combined with breast-conserving surgery. The short-term efficacy, surgical indicators and quality of life were compared between the two groups; Her-2 and Ki67, tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and Carbohydrate antigen 153 (CA153)] were different before and after treatment. Results: The overall effective rate in the observation group (91.11%) was higher than that in the control group (75.56%) (P<0.05). The observation group had less intraoperative bleeding than the control group, fewer complications than the control group, and shorter operative time than the control group (P<0.05). The KPS scores of early breast cancer patients in the 2 groups were higher after treatment than before treatment (P<0.05); the magnitude of difference before and after treatment was higher in the observation group than in the control group (P<0.05).Serum Her-2 and Ki67 levels were lower in the 2 groups than before treatment (P<0.05); the difference in the observation group was higher than that in the control group before and after treatment (P<0.05). Serum CEA, CA125 and CA153 levels were lower in the 2 groups than before treatment (P<0.05); the difference in the observation group was higher than that in the control group before and after treatment (P<0.05). Conclusion: Neoadjuvant chemotherapy combined with breast-conserving surgery is effective in the near term for patients with early-stage breast cancer, significantly improving the quality of survival, reducing Her-2 and Ki67 levels, and lowering CEA, CA125 and CA153 levels.
王晓娇, 练孝春, 韩涛, 陈俊升, 齐向永, 黄坤. 新辅助化疗联合保乳术对早期乳腺癌患者的临床运用分析[J]. 河北医学, 2022, 28(11): 1887-1890.
WANG Xiaojiao, LIAN Xiaochun, HAN Tao, et al. Clinical Application of Neoadjuvant Chemotherapy Combined with Breast Conserving Surgery in Patients with Early-Stage Breast Cancer. HeBei Med, 2022, 28(11): 1887-1890.
[1] Barough NB,Sajjadian F,Jalilzadeh N,et al.Understanding breast cancer heterogeneity through non-genetic heterogeneity[J].Breast Cancer,2021,28(4):777-791. [2] Tien TZ,Lee JLW,Lim JCT,et al.Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence[J].Histopathology,2021,79(2):139-159. [3] 张恒乐,张晓宇,康晓宁,等.新辅助化疗联合保乳手术治疗三阴性乳腺癌40例分析[J].中国医学前沿杂志(电子版),2022,14(4):59-62. [4] Gupta P,Neupane YR,Parvez S,et al.Recent advances in targeted nanotherapeutic approaches for breast cancer management[J].Nanomedicine,2021,16(29):2605-2631. [5] 王卫芹,牛烁,陈学东.保乳手术治疗早期乳腺癌的疗效及miR-21和miR-155表达的研究[J].转化医学杂志,2021,10(2):89-92,107. [6] 梁欣,刘维,荆海红.早期乳腺癌患者改良根治术与保乳手术治疗的效果及对患者术后生活质量的影响[J].实用癌症杂志,2021,36(5):793-795. [7] 王平,彭永强,王晓东,等.新辅助化疗CAF方案联合保乳手术治疗乳腺癌患者对免疫功能及近期预后的影响[J].湖南师范大学学报(医学版),2021,18(4):201-204. [8] 罗斯译,柴利,阮思蓓,等.川南地区乳腺癌患者人表皮生长因子受体2基因状态及其蛋白表达与临床病理特征的关系[J].实用医学杂志,2020,36(1):22-26. [9] 何美情,王娟,刘波,等.乳腺癌组织中HER-2的表达与肿瘤超声声像图特征的相关性[J].现代肿瘤医学,2021,29(20):3565-3568. [10] 李明.三阴性乳腺癌患者癌组织中雄激素受体、Ki67的表达及与预后的关系[J].中国综合临床,2022,38(2):164-169. [11] 秦燕,陈英,陈雷.CEA、CA153、CA125与乳腺癌临床病理因素的关系[J].分子诊断与治疗杂志,2021,13(11):1761-1764,1769.
2022, Vol. 28 
冀公网安备13080202000677号